Brief: Vistagen Announces Positive Top-Line Results From Phase 3 Palisade-2 Trial Of Fasedienol Nasal Spray In Social Anxiety Disorder

Vistagen Therapeutics

07/08/2023 16:24

Aug 7 (Reuters) - VistaGen Therapeutics Inc  VTGN.O :
    * VISTAGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3
PALISADE-2 TRIAL OF FASEDIENOL (PH94B) NASAL SPRAY IN SOCIAL
ANXIETY DISORDER
    * VISTAGEN THERAPEUTICS INC - TRIAL MET ITS PRIMARY
ENDPOINT,
    * VISTAGEN THERAPEUTICS - FASEDIENOL WAS WELL-TOLERATED AND
DEMONSTRATED A FAVORABLE SAFETY PROFILE
    * VISTAGEN THERAPEUTICS INC - TRIAL ALSO MET ITS SECONDARY
ENDPOINT
    * VISTAGEN - TRIAL MET EXPLORATORY ENDPOINT OF DIFFERENCE IN
PROPORTION OF PATIENT-ASSESSED RESPONDERS BETWEEN FASEDIENOL AND
PLACEBO
    * VISTAGEN THERAPEUTICS INC - ALL TREATMENT-EMERGENT ADVERSE
EVENTS REPORTED FOR OVERALL STUDY WERE MILD OR MODERATE
    * VISTAGEN THERAPEUTICS INC - THERE WERE NO AES REPORTED IN
FASEDIENOL TREATMENT ARM ABOVE 2% OCCURRENCE

Source text for Eikon:  ID:nBw3QSJQla 
Further company coverage:  VTGN.O